Get started
Author

Elizabeth Kumm

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
2010 · A Younes, J M Vose, et al. · British Journal of Cancer · 132
PDF
Results of a Phase 2 Trial of HGS-ETR1 (Agonistic Human Monoclonal Antibody to TRAIL Receptor 1) in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL).
2005 · Anas Younes, Julie M. Vose, et al. · Blood · 71
Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer
2014 · Emiliano Calvo, Victor J. Chen, et al. · Investigational New Drugs · 57
A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI.
2007 · Branimir I. Šikić, Heather A. Wakelee, et al. · UCL Discovery (University College London) · 36
Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997.
2004 · Ian W. Flinn, Elizabeth Kumm, et al. · Blood · 33
A randomized phase II trial of mapatumumab, a TRAIL-R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC.
2010 · J. Von Pawel, J. H. Harvey, et al. · Journal of Clinical Oncology · 25
A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)
2010 · Andrew Belch, Atul Sharma, et al. · Blood · 22
A randomized phase IItrial of mapatumumab, a TRAIL R1 agonist monoclonal antibody, in combination with carboplatin and paclitaxel in patients with advanced NSCLC
2011 · J von Pawel, J Harvey, et al. · Pneumologie · 1
進行性nsclc患者におけるカルボプラチンとパクリタキセルを併用した,trail-r1アゴニスト単クローン抗体マパツムマブの無作為化第2相試験
2010 · Joachim von Pawel, J H Harvey, et al. · Journal of Clinical Oncology · 1
586 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer
2012 · E. Calvo, N. Dickgreber, et al. · European Journal of Cancer
[Meeting Abstract] A phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI
2007 · Branimir I. Sikic, Heather A. Wakelee, et al. · Newcastle University ePrints (Newcastle Univesity)
Works count: 11
Citation count: 378
H-index: 7
I10-index: 7
Year
Topic
Type